Clinical trials: Melanoma
Melanoma
Evaluation of Pigmented Skin Lesions With MelaFind(R) System
The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective.
- Trial name
- NCT00434057
- Testing
- MelaFind(R)
- Where
- 2 sites in United States
- Volunteers
- 1,383 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Advanced Cancer, Metastatic Cancer
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumors
- Trial name
- STMN1-LP (NCT01505153)
- Testing
- pbi-shRNA STMN1 LP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gradalis, Inc.
Neoplasms
Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
The study will be conducted as an open label, single-dose, explorative study with patients with histologically proven cancer and, preferably, tumor positive lesions in previously performed nuclear medicine imaging examinations.
- Trial name
- NCT01186601
- Testing
- PET tracer (BAY94-9392)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lantheus Biosciences Ltd.
Stage III/IV Melanoma
Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment
Keynote 695 is Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab.
- Trial name
- Keynote-695 (NCT03132675)
- Testing
- tavokinogene telseplasmid, Pembrolizumab, ImmunoPulse
- Where
- 33 sites in United States, Australia and 3 more
- Volunteers
- 143 people
- Sponsor
- OncoSec Medical Incorporated
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Melanoma
Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of…
- Trial name
- NCT00701987
- Testing
- ALS-357
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Advanced Life Sciences, Inc.
Cutaneous Melanoma
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
The EXPAND Registry Study follows patients with cutaneous melanoma who have had the DecisionDx-Melanoma gene expression assay performed as part of their clinical care.
- Trial name
- EXPAND (NCT02355587)
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Castle Biosciences Incorporated
Melanoma (Skin), Metastatic Melanoma
A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients
1. Background The purpose of this study is to describe the profile of patients with BRAF-mutated melanoma treated with BRAF/MEK inhibitors combination and using the Tavie Skin application.
- Conditions
- Melanoma (Skin), Metastatic Melanoma, BRAF V600 Mutation
- Trial name
- TavieSkin (NCT04911998)
- Where
- Portugal
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament
Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have an advanced malignancy (cancer) or stage IV melanoma.
- Trial name
- NCT00073892
- Testing
- PI-88
- Where
- 5 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Cellxpert Biotechnology Corp.
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Oncology, MEK Mutation
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway…
- Conditions
- Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation
- Trial name
- NST-628 (NCT06326411)
- Testing
- NST-628
- Where
- 23 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Nested Therapeutics, Inc
Melanoma Stage III, Melanoma (Skin)
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
This study is an open-label, randomized, comparative phase III study, which will include subjects with resectable stage III skin melanoma (up to 3 resectable transient metastases are acceptable).
- Trial name
- NEO-MIMAJOR (NCT05751928)
- Testing
- BCD-217, anti-PD1, Excision of the primary lesion
- Where
- 36 sites in Belarus, Russia
- Volunteers
- 411 people
- Sponsor
- Biocad
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Melanoma
Trial of pIL-12 Electroporation Malignant Melanoma
This study will assess the safety and effectiveness of different dosing regimens of ImmunoPulse IL-12® in malignant melanoma. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene…
- Trial name
- IL-12MEL (NCT01502293)
- Testing
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- OncoSec Medical Incorporated
Metastatic Uveal Melanoma
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or…
- Trial name
- NCT05987332
- Testing
- IDE196, Crizotinib, Pembrolizumab
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 420 people
- Sponsor
- IDEAYA Biosciences
Metastatic Melanoma
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
This is a phase Ib/II clinical trial to test safety and efficacy of combining CD24Fc with ipilimumab and nivolumab to decrease irAE, with built-in interim analyses, and safety and response stopping rules.
- Trial name
- CINDI (NCT04060407)
- Testing
- CD24Fc, Ipilimumab, Nivolumab
- Where
- United States
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Solid Tumors
Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab
HBM4003 in combination with Toripalimab. The expected duration of treatment for each subject will vary according to the number of cycles completed; the number of cycles will depend on whether the subject benefits from the…
- Trial name
- NCT04727164
- Testing
- HBM4003 and Triprilimab
- Volunteers
- 61 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Melanoma
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
This study will evaluate the safety and efficacy of 2 different dosing schedules of pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2 schedules to treatment with ipilimumab in…
- Trial name
- NCT01866319
- Testing
- Pembrolizumab, Ipilimumab
- Volunteers
- 834 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Melanoma
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04303169
- Testing
- Pembrolizumab, Vibostolimab, Gebasaxturev
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.